74 related articles for article (PubMed ID: 25198658)
1. Regulation of MET kinase inhibitor resistance by copy number of MET in gastric carcinoma cells.
Funakoshi Y; Mukohara T; Ekyalongo RC; Tomioka H; Kataoka Y; Shimono Y; Chayahara N; Toyoda M; Kiyota N; Fujiwara Y; Minami H
Oncol Res; 2013; 21(6):287-93. PubMed ID: 25198658
[TBL] [Abstract][Full Text] [Related]
2. Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line.
Funakoshi Y; Mukohara T; Tomioka H; Ekyalongo RC; Kataoka Y; Inui Y; Kawamori Y; Toyoda M; Kiyota N; Fujiwara Y; Minami H
Invest New Drugs; 2013 Oct; 31(5):1158-68. PubMed ID: 23568717
[TBL] [Abstract][Full Text] [Related]
3. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
[TBL] [Abstract][Full Text] [Related]
4. Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation.
Suda K; Tomizawa K; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
Lung Cancer; 2012 Jun; 76(3):292-9. PubMed ID: 22133747
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Src impairs the growth of met-addicted gastric tumors.
Bertotti A; Bracco C; Girolami F; Torti D; Gastaldi S; Galimi F; Medico E; Elvin P; Comoglio PM; Trusolino L
Clin Cancer Res; 2010 Aug; 16(15):3933-43. PubMed ID: 20628031
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of c-Met expression does not enhance the sensitivity of gastric cancer cell line MKN-45 to gefitinib.
Ma JA; Hu C; Li W; Ren J; Zou F; Zhou D; Zou W; Wei Y; Zhou Y
Mol Med Rep; 2015 Mar; 11(3):2269-75. PubMed ID: 25395073
[TBL] [Abstract][Full Text] [Related]
8. Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
Ahn SY; Kim J; Kim MA; Choi J; Kim WH
Anticancer Res; 2017 Mar; 37(3):1127-1138. PubMed ID: 28314274
[TBL] [Abstract][Full Text] [Related]
9. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
10. MET amplification as a potential therapeutic target in gastric cancer.
Kawakami H; Okamoto I; Arao T; Okamoto W; Matsumoto K; Taniguchi H; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K; Yamada Y
Oncotarget; 2013 Jan; 4(1):9-17. PubMed ID: 23327903
[TBL] [Abstract][Full Text] [Related]
11. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.
Kataoka Y; Mukohara T; Tomioka H; Funakoshi Y; Kiyota N; Fujiwara Y; Yashiro M; Hirakawa K; Hirai M; Minami H
Invest New Drugs; 2012 Aug; 30(4):1352-60. PubMed ID: 21655918
[TBL] [Abstract][Full Text] [Related]
12. Crizotinib-resistant
Shen B; Wu F; Ye J; Liang R; Wang R; Yu R; Wu X; Shao YW; Feng J
Future Oncol; 2019 Aug; 15(22):2585-2593. PubMed ID: 31339066
[No Abstract] [Full Text] [Related]
13. Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion.
Asaoka Y; Tada M; Ikenoue T; Seto M; Imai M; Miyabayashi K; Yamamoto K; Yamamoto S; Kudo Y; Mohri D; Isomura Y; Ijichi H; Tateishi K; Kanai F; Ogawa S; Omata M; Koike K
Biochem Biophys Res Commun; 2010 Apr; 394(4):1042-6. PubMed ID: 20331976
[TBL] [Abstract][Full Text] [Related]
14. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
Yoshida T; Okamoto I; Okamoto W; Hatashita E; Yamada Y; Kuwata K; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Cancer Sci; 2010 Jan; 101(1):167-72. PubMed ID: 19804422
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
[TBL] [Abstract][Full Text] [Related]
16. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.
Fujino T; Kobayashi Y; Suda K; Koga T; Nishino M; Ohara S; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
J Thorac Oncol; 2019 Oct; 14(10):1753-1765. PubMed ID: 31279006
[TBL] [Abstract][Full Text] [Related]
18. Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer.
Francica P; Nisa L; Aebersold DM; Langer R; Bladt F; Blaukat A; Stroka D; Martínez MR; Zimmer Y; Medová M
Clin Cancer Res; 2016 Nov; 22(21):5322-5336. PubMed ID: 27185371
[TBL] [Abstract][Full Text] [Related]
19. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.
Suda K; Mizuuchi H; Maehara Y; Mitsudomi T
Cancer Metastasis Rev; 2012 Dec; 31(3-4):807-14. PubMed ID: 22736441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
